首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1661093

2025 年至 2033 年阿茲海默症藥物市場報告，按藥物類別（多奈哌齊、加蘭他敏、利伐斯的明、美金剛等）、配銷通路（醫院藥房、零售藥房、網路商店等）和地區分類

Alzheimer's Drugs Market Report by Drug Class (Donepezil, Galantamine, Rivastigmine, Memantine, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores, and Others), and Region 2025-2033

出版日期: 2025年02月10日 | 出版商:

IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

2024IMARC Group全球阿茲海默症藥物市場規模達到 81 億美元。阿茲海默症病患病率的上升、藥物研發的眾多進步以及公共和私人對神經退化性疾病研究的資助不斷增加是推動市場發展的一些主要因素。

阿茲海默症藥物是指專門設計用於緩解阿茲海默症症狀或減緩其進展的藥物化合物和療法。他們的目標是解決大腦中潛在的病理生理變化，例如澱粉樣蛋白斑塊和 tau 纏結的積累，這些都是阿茲海默症的特徵。它們主要分為兩大類，包括膽鹼酯酶抑制劑和 NMDA 受體拮抗劑。膽鹼酯酶抑制劑，如多奈哌齊、利凡斯的明和加蘭他敏，透過提高大腦中的神經傳導物質水平，暫時增強認知功能。 NMDA 受體拮抗劑，例如美金剛，可調節麩胺酸活性，有助於緩解認知和行為症狀。

阿茲海默症的盛行率不斷上升，需要有效的治療，這將在預測期內刺激阿茲海默症藥物市場的成長。此外，由於神經科學的眾多進步和對疾病潛在機制的更深入了解，主要參與者不斷加強研發力度，從而發現潛在的治療劑，對市場成長產生了積極影響。此外，政府和組織對神經退化性疾病研究的資金分配增加，為藥物開發創造了有利的環境，催化了市場成長。除此之外，老齡人口的不斷增加（特別是在已開發地區）正在推動市場成長，因為老年人更容易罹患阿茲海默症。此外，新藥和新療法的法規核准不斷升級，為製藥公司進入和擴大市場佔有率創造了機會，從而促進了市場成長。

阿茲海默症藥物市場趨勢/促進因素：

疾病盛行率上升

阿茲海默症的盛行率不斷上升是支持市場成長的關鍵因素之一。這可以歸因於全球人口的快速老化。隨著人們壽命的延長，包括阿茲海默症在內的與年齡相關的神經退化性疾病的發生率激增。這種人口結構的改變給全球醫療保健系統帶來了越來越重的負擔，需要有效的治療。製藥公司正在透過投資開發能夠緩解症狀或潛在減緩病情進展的藥物來滿足這一需求。此外，隨著越來越多的病例被發現，認知的提高和早期診斷也導致患病率上升。因此，盛行率因素推動了市場發展，並強調了研究和創新的迫切需要，以應對阿茲海默症帶來的醫療保健挑戰。

研究進展迅速

在分子和細胞層面上對阿茲海默症的理解的進步是市場的關鍵驅動力。研究人員正在揭示疾病背後的複雜機制，包括澱粉樣斑塊和 tau 蛋白纏結在腦部退化中的作用。這些見解為藥物開發提供了有價值的目標。此外，遺傳學研究揭示了增加阿茲海默症易感性的遺傳因素，進一步指導藥物研發工作。基因組學、神經成像和生物標記分析等尖端技術正在促進臨床試驗和藥物療效評估。這些由研究驅動的發展有助於擴大潛在阿茲海默症藥物的範圍並提高其有效性，為改善患者的治療效果帶來希望。

增加政府資金和支持

世界各國政府和醫療保健組織越來越認知到阿茲海默症是一場公共衛生危機。該疾病造成的巨大經濟和社會影響，包括護理人員的負擔和醫療保健費用，導致對阿茲海默症研究和藥物開發計劃的資金增加。政府補助、研究夥伴關係以及針對製藥公司的激勵措施已變得更加普遍。這項資金支持增強了正在進行的研究工作，並鼓勵製藥業投資阿茲海默症藥物研發。此外，監管機構正在簡化阿茲海默症藥物的核准流程，以促進藥物更快進入市場。在這種公共和私營部門支持的合作環境中，製藥公司受到激勵進行創新並將有效的阿茲海默症治療方法推向市場，解決全球緊迫的醫療保健需求。

市場結構
關鍵參與者
關鍵參與者簡介
- Abbvie Inc.
- AstraZeneca PLC
- Biogen Inc.
- Daiichi Sankyo Company Limited
- Eisai Co. Ltd.
- Eli Lilly and Company
- H. Lundbeck A/S
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- Novartis AG
- Ono Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Teva Pharmaceutical Industries Limited

簡介目錄圖表

Product Code: SR112025A2695

The global Alzheimer's drugs market size reached USD 8.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 12.9 Billion by 2033, exhibiting a growth rate (CAGR) of 5.07% during 2025-2033. The rising prevalence of Alzheimer's disease, numerous advancements in drug development, and increasing public and private funding for neurodegenerative disease research are some of the major factors propelling the market.

Alzheimer's drugs refer to pharmaceutical compounds and therapies specifically designed to mitigate the symptoms or slow the progression of Alzheimer's disease, a prevalent neurodegenerative disorder that primarily affects cognitive functions. They aim to address the underlying pathophysiological changes in the brain, such as the accumulation of amyloid plaques and tau tangles, which are characteristic of Alzheimer's disease. They fall into two main categories, including cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors, like donepezil, rivastigmine, and galantamine, work by boosting the levels of neurotransmitters in the brain, enhancing cognitive function temporarily. NMDA receptor antagonists, such as memantine, regulate glutamate activity, aid in providing relief from cognitive and behavioral symptoms.

The rising prevalence of Alzheimer's disease that necessitates effective treatments will stimulate the growth of the Alzheimer's drugs market during the forecast period. Moreover, the increasing research and development efforts by key players due to numerous advancements in neuroscience and a deeper understanding of the disease's underlying mechanisms, leading to the discovery of potential therapeutic agents, is positively influencing market growth. Additionally, the rise in funding allocations by governments and organizations for neurodegenerative disease research, facilitating a conducive environment for drug development, has catalyzed market growth. Besides this, the expanding aging population, particularly in developed regions, is propelling market growth as the elderly are more susceptible to Alzheimer's disease. Furthermore, the escalating regulatory approvals for novel drugs and therapies that creates opportunities for pharmaceutical companies to enter and expand their presence is contributing to market growth.

Alzheimer's Drugs Market Trends/Drivers:

Rising prevalence of the disease

The escalating prevalence of Alzheimer's disease is one of the key factors supporting the market growth. This can be attributed to the rapidly aging population worldwide. As people live longer, the incidence of age-related neurodegenerative disorders, including Alzheimer's, has surged. This demographic shift places an ever-increasing burden on global healthcare systems and necessitates effective treatments. Pharmaceutical companies are responding to this demand by investing in the development of drugs that can alleviate symptoms or potentially slow down disease progression. Moreover, heightened awareness and early diagnosis contribute to the rising prevalence as more cases are identified. As a result, the prevalence factor drives the market and underscores the urgent need for research and innovation to address the healthcare challenges posed by Alzheimer's disease.

Rapid advancements in research

Advances in the understanding of Alzheimer's disease at the molecular and cellular levels are pivotal drivers in the market. Researchers are unraveling the complex mechanisms behind the disease, including the role of amyloid plaques and tau protein tangles in brain degeneration. These insights provide valuable targets for drug development. Additionally, genetics research is revealing the hereditary factors that increase susceptibility to Alzheimer's, further guiding drug discovery efforts. Cutting-edge technologies, such as genomics, neuroimaging, and biomarker analysis, are facilitating clinical trials and drug efficacy assessments. These research-driven developments are instrumental in expanding the repertoire of potential Alzheimer's drugs and enhancing their effectiveness, offering hope for improved patient outcomes.

Increasing government funding and support

Governments and healthcare organizations across the globe are increasingly recognizing Alzheimer's disease as a public health crisis. The substantial economic and social impact of the disease, including caregiver burden and healthcare costs, has led to a rise in funding for Alzheimer's research and drug development initiatives. Government grants, research partnerships, and incentives for pharmaceutical companies have become more prevalent. This financial support bolsters ongoing research efforts and encourages the pharmaceutical industry to invest in Alzheimer's drug development. Moreover, regulatory agencies are streamlining approval processes for Alzheimer's drugs, facilitating faster market entry. In this collaborative environment of public and private sector support, pharmaceutical companies are incentivized to innovate and bring effective Alzheimer's treatments to the market, addressing a pressing global healthcare need.

Alzheimer's Drugs Industry Segmentation:

Breakup by Drug Class:

Donepezil
Galantamine
Rivastigmine
Memantine
Others

Donepezil represents the most popular drug class

Donepezil is a medication categorized as a cholinesterase inhibitor, commonly used in the treatment of Alzheimer's disease. It works by increasing the levels of certain neurotransmitters in the brain, helping to improve cognitive function and alleviate some of the symptoms associated with Alzheimer's, such as memory loss, confusion, and problems with thinking and reasoning.

Furthermore, donepezil, along with similar drugs like rivastigmine and galantamine, plays a pivotal role in driving the market growth. These drugs are often prescribed to patients with Alzheimer's to manage their symptoms, providing relief and enhancing their quality of life. As the global prevalence of Alzheimer's continues to rise, there is an increasing demand for such drugs. This growing demand encourages pharmaceutical companies to invest in research and development, striving to innovate and improve upon existing treatments, thus contributing to the expansion of the Alzheimer's drugs market.

Breakup by Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Stores
Others

Hospital pharmacy accounts for the majority of the market share

Hospital pharmacy refers to the specialized pharmacy practice within healthcare institutions, such as hospitals and medical centers. Its primary role is to ensure the safe and effective use of medications for inpatients and outpatients. Hospital pharmacists work closely with healthcare teams to provide medication therapy management, including drug dispensing, monitoring, and patient education. Hospital pharmacies play a crucial role in fueling the market expansion as they are instrumental in the distribution and administration of Alzheimer's medications. They serve as a pivotal link between pharmaceutical companies, healthcare providers, and patients, ensuring that Alzheimer's drugs reach the right individuals at the right time.

Moreover, hospital pharmacists contribute to patient education and adherence, optimizing the effectiveness of these drugs. The growth of the Alzheimer's drugs market is related to the efficient and patient-focused services provided by hospital pharmacies, as they facilitate the delivery of these vital medications to those in need.

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest share in the market since the region has a significant and growing geriatric population, and Alzheimer's primarily affects older individuals. This demographic trend increases the demand for Alzheimer's drugs. Moreover, North America boasts a robust healthcare infrastructure, which includes advanced research facilities and pharmaceutical companies at the forefront of Alzheimer's drug development. These companies conduct clinical trials and research initiatives that contribute to innovation in the field.

Additionally, regulatory bodies like the FDA in the United States play a crucial role in drug approvals, setting the standard for global markets. Apart from this, North America has a high level of awareness about Alzheimer's disease, leading to early diagnosis and greater use of available treatments. Furthermore, North America's well-established healthcare reimbursement systems and patient advocacy groups actively support access to Alzheimer's drugs, fostering an environment that drives market growth and encourages pharmaceutical innovation in the region.

Competitive Landscape:

Key players in the Alzheimer's drugs industry have been instrumental in driving recent innovations. Notably, a groundbreaking FDA-approved drug from one of these major pharmaceutical companies directly targets amyloid plaques, marking a significant advancement in Alzheimer's treatment. Other key players are pioneering therapies that enhance amyloid clearance and simultaneously address tau pathology, both of which have shown promise in clinical trials. Beyond traditional drug development, these companies are exploring innovative approaches, including anti-inflammatory drugs, to combat neuroinflammation associated with Alzheimer's. Additionally, digital health technologies have been integrated into their strategies, with the introduction of cognitive assessment tools and digital biomarkers, revolutionizing early detection and monitoring of Alzheimer's. The efforts of these industry players signify a dynamic and comprehensive approach to tackle this complex neurodegenerative disease.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.
AstraZeneca PLC
Biogen Inc.
Daiichi Sankyo Company Limited
Eisai Co. Ltd.
Eli Lilly and Company
H. Lundbeck A/S
F. Hoffmann-La Roche AG
Merck & Co. Inc.
Novartis AG
Ono Pharmaceutical Co. Ltd.
Pfizer Inc
Teva Pharmaceutical Industries Limited

Key Questions Answered in This Report:

How has the global alzheimer's drugs market performed so far and how will it perform in the coming years ?
What has been the impact of COVID-19 on the global alzheimer's drugs market ?
What are the key regional markets ?
What is the breakup of the market based on the drug class ?
What is the breakup of the market based on the distribution channel ?
What are the various stages in the value chain of the industry ?
What are the key driving factors and challenges in the industry ?
What is the structure of the global alzheimer's drugs market and who are the key players ?
What is the degree of competition in the industry ?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Alzheimer's Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Class

6.1 Donepezil
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Galantamine
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Rivastigmine
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Memantine
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast

7 Market Breakup by Distribution Channel

7.1 Hospital Pharmacy
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Retail Pharmacy
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Online Stores
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by Region

8.1 North America
- 8.1.1 United States
  - 8.1.1.1 Market Trends
  - 8.1.1.2 Market Forecast
- 8.1.2 Canada
  - 8.1.2.1 Market Trends
  - 8.1.2.2 Market Forecast
8.2 Asia Pacific
- 8.2.1 China
  - 8.2.1.1 Market Trends
  - 8.2.1.2 Market Forecast
- 8.2.2 Japan
  - 8.2.2.1 Market Trends
  - 8.2.2.2 Market Forecast
- 8.2.3 India
  - 8.2.3.1 Market Trends
  - 8.2.3.2 Market Forecast
- 8.2.4 South Korea
  - 8.2.4.1 Market Trends
  - 8.2.4.2 Market Forecast
- 8.2.5 Australia
  - 8.2.5.1 Market Trends
  - 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
  - 8.2.6.1 Market Trends
  - 8.2.6.2 Market Forecast
- 8.2.7 Others
  - 8.2.7.1 Market Trends
  - 8.2.7.2 Market Forecast
8.3 Europe
- 8.3.1 Germany
  - 8.3.1.1 Market Trends
  - 8.3.1.2 Market Forecast
- 8.3.2 France
  - 8.3.2.1 Market Trends
  - 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
  - 8.3.3.1 Market Trends
  - 8.3.3.2 Market Forecast
- 8.3.4 Italy
  - 8.3.4.1 Market Trends
  - 8.3.4.2 Market Forecast
- 8.3.5 Spain
  - 8.3.5.1 Market Trends
  - 8.3.5.2 Market Forecast
- 8.3.6 Russia
  - 8.3.6.1 Market Trends
  - 8.3.6.2 Market Forecast
- 8.3.7 Others
  - 8.3.7.1 Market Trends
  - 8.3.7.2 Market Forecast
8.4 Latin America
- 8.4.1 Brazil
  - 8.4.1.1 Market Trends
  - 8.4.1.2 Market Forecast
- 8.4.2 Mexico
  - 8.4.2.1 Market Trends
  - 8.4.2.2 Market Forecast
- 8.4.3 Others
  - 8.4.3.1 Market Trends
  - 8.4.3.2 Market Forecast
8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast

9 SWOT Analysis

9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
- 13.3.1 Abbvie Inc.
  - 13.3.1.1 Company Overview
  - 13.3.1.2 Product Portfolio
  - 13.3.1.3 Financials
  - 13.3.1.4 SWOT Analysis
- 13.3.2 AstraZeneca PLC
  - 13.3.2.1 Company Overview
  - 13.3.2.2 Product Portfolio
  - 13.3.2.3 Financials
  - 13.3.2.4 SWOT Analysis
- 13.3.3 Biogen Inc.
  - 13.3.3.1 Company Overview
  - 13.3.3.2 Product Portfolio
  - 13.3.3.3 Financials
  - 13.3.3.4 SWOT Analysis
- 13.3.4 Daiichi Sankyo Company Limited
  - 13.3.4.1 Company Overview
  - 13.3.4.2 Product Portfolio
  - 13.3.4.3 Financials
  - 13.3.4.4 SWOT Analysis
- 13.3.5 Eisai Co. Ltd.
  - 13.3.5.1 Company Overview
  - 13.3.5.2 Product Portfolio
  - 13.3.5.3 Financials
  - 13.3.5.4 SWOT Analysis
- 13.3.6 Eli Lilly and Company
  - 13.3.6.1 Company Overview
  - 13.3.6.2 Product Portfolio
  - 13.3.6.3 Financials
  - 13.3.6.4 SWOT Analysis
- 13.3.7 H. Lundbeck A/S
  - 13.3.7.1 Company Overview
  - 13.3.7.2 Product Portfolio
  - 13.3.7.3 Financials
  - 13.3.7.4 SWOT Analysis
- 13.3.8 F. Hoffmann-La Roche AG
  - 13.3.8.1 Company Overview
  - 13.3.8.2 Product Portfolio
  - 13.3.8.3 SWOT Analysis
- 13.3.9 Merck & Co. Inc.
  - 13.3.9.1 Company Overview
  - 13.3.9.2 Product Portfolio
  - 13.3.9.3 Financials
  - 13.3.9.4 SWOT Analysis
- 13.3.10 Novartis AG
  - 13.3.10.1 Company Overview
  - 13.3.10.2 Product Portfolio
  - 13.3.10.3 Financials
  - 13.3.10.4 SWOT Analysis
- 13.3.11 Ono Pharmaceutical Co. Ltd.
  - 13.3.11.1 Company Overview
  - 13.3.11.2 Product Portfolio
  - 13.3.11.3 Financials
  - 13.3.11.4 SWOT Analysis
- 13.3.12 Pfizer Inc.
  - 13.3.12.1 Company Overview
  - 13.3.12.2 Product Portfolio
  - 13.3.12.3 Financials
  - 13.3.12.4 SWOT Analysis
- 13.3.13 Teva Pharmaceutical Industries Limited
  - 13.3.13.1 Company Overview
  - 13.3.13.2 Product Portfolio
  - 13.3.13.3 Financials
  - 13.3.13.4 SWOT Analysis

簡介目錄圖表

List of Figures

Figure 1: Global: Alzheimer's Drugs Market: Major Drivers and Challenges
Figure 2: Global: Alzheimer's Drugs Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Alzheimer's Drugs Market: Breakup by Drug Class (in %), 2024
Figure 4: Global: Alzheimer's Drugs Market: Breakup by Distribution Channel (in %), 2024
Figure 5: Global: Alzheimer's Drugs Market: Breakup by Region (in %), 2024
Figure 6: Global: Alzheimer's Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 7: Global: Alzheimer's Drugs (Donepezil) Market: Sales Value (in Million USD), 2019 & 2024
Figure 8: Global: Alzheimer's Drugs (Donepezil) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 9: Global: Alzheimer's Drugs (Galantamine) Market: Sales Value (in Million USD), 2019 & 2024
Figure 10: Global: Alzheimer's Drugs (Galantamine) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 11: Global: Alzheimer's Drugs (Rivastigmine) Market: Sales Value (in Million USD), 2019 & 2024
Figure 12: Global: Alzheimer's Drugs (Rivastigmine) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: Global: Alzheimer's Drugs (Memantine) Market: Sales Value (in Million USD), 2019 & 2024
Figure 14: Global: Alzheimer's Drugs (Memantine) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Global: Alzheimer's Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
Figure 16: Global: Alzheimer's Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Global: Alzheimer's Drugs (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
Figure 18: Global: Alzheimer's Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Global: Alzheimer's Drugs (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
Figure 20: Global: Alzheimer's Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 21: Global: Alzheimer's Drugs (Online Stores) Market: Sales Value (in Million USD), 2019 & 2024
Figure 22: Global: Alzheimer's Drugs (Online Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 23: Global: Alzheimer's Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
Figure 24: Global: Alzheimer's Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 25: North America: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 26: North America: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 27: United States: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 28: United States: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 29: Canada: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 30: Canada: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 31: Asia Pacific: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 32: Asia Pacific: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 33: China: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 34: China: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 35: Japan: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 36: Japan: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 37: India: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 38: India: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 39: South Korea: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 40: South Korea: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 41: Australia: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 42: Australia: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 43: Indonesia: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 44: Indonesia: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 45: Others: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 46: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 47: Europe: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 48: Europe: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 49: Germany: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 50: Germany: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 51: France: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 52: France: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 53: United Kingdom: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 54: United Kingdom: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 55: Italy: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 56: Italy: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 57: Spain: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 58: Spain: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 59: Russia: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 60: Russia: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 61: Others: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 62: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 63: Latin America: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 64: Latin America: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 65: Brazil: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 66: Brazil: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 67: Mexico: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 68: Mexico: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 69: Others: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 70: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 71: Middle East and Africa: Alzheimer's Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 72: Middle East and Africa: Alzheimer's Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 73: Global: Alzheimer's Drugs Industry: SWOT Analysis
Figure 74: Global: Alzheimer's Drugs Industry: Value Chain Analysis
Figure 75: Global: Alzheimer's Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Alzheimer's Drugs Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Alzheimer's Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
Table 3: Global: Alzheimer's Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
Table 4: Global: Alzheimer's Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 5: Global: Alzheimer's Drugs Market: Competitive Structure
Table 6: Global: Alzheimer's Drugs Market: Key Players

02-2729-4219

+886-2-2729-4219